News

CEPI, THSTI, Panacea Biotec partner for Betacoronavirus vaccines

CEPI will provide funding of up to $12.5m to support the development of multi-epitope, nanoparticle-based vaccine candidates and advance the manufacturing process

CEPI, the Coalition for Epidemic Preparedness Innovations, announced the latest award under its $200m programme, launched in March 2021, to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other Betacoronaviruses. 

CEPI will partner with a consortium comprised of the Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology, Government of India and Panacea Biotec, a research-based biopharmaceutical company and vaccine manufacturer, to develop vaccine candidates that could provide broad protection against SARS-Cov-2 variants and other Betacoronaviruses.

CEPI will provide funding of up to $12.5m to support the development of multi-epitope, nanoparticle-based vaccine candidates and advance the manufacturing process. Through this research programme, THSTI and Panacea Biotec will design and select the lead antigen through proof-of-concept preclinical studies, and undertake initial clinical development through Phase I/II studies as they seek to establish clinical proof of concept for novel vaccine candidates to provide broad protection against MERS, SARS-CoV, SARS-CoV-2 and its variants.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
IndiaMedToday
Close
Close